MAD-ID 2018

PROGRAMMATIC LEARNING OBJECTIVES

As an attendee of MAD-ID 2018, you will be able to earn up to 18 Continuing Pharmacy Education hours (1.8 CEU) or 18 Continuing Medical Education hours (AMA PRA Category 1 Credits™).  At the conclusion of this activity, you should be able to:

Depending on which four classroom/workshop sessions the participant attends, four of the following eight learning objectives should be achieved:

  1. Describe and dramatize techniques that can be used to improve communication between health care professionals and patients and apply this to your own practice
  2. Select strategies to encourage expansion of antimicrobial stewardship across a health system and prioritize ASP objectives and
  3. Design an effective therapeutic drug monitoring plan for vancomycin using area-under-the-curve estimation, and discuss strategies for improving AUC- based TDM in
  4. Recommend strategies for marketing antimicrobial stewardship programs to key internal and external
  5. Outline the steps to design, assess, and present a quality improvement or research project and apply this to evaluating the impact of an antimicrobial stewardship
  6. Select solutions and strategies to meet The Joint Commission standards for antimicrobial stewardship and apply them to your practice setting
  7. Explain the process of tracking and reporting antibiotic use and identify an opportunity to apply benchmarking reports in your
  8. Discuss the impact of penicillin allergy label on appropriate antimicrobial therapy and propose an antimicrobial stewardship intervention to clarify penicillin allergy labels

The following learning objective relate to the remaining educational sessions:

  1. Describe the epidemiology of multidrug resistant Gram-negative infections and explain the role of antimicrobial stewardship programs in optimizing antimicrobial therapy
  2. List examples of how biomarkers can be implemented to improve antimicrobial use and outcomes
  3. Summarize the evidence for and against implementation of extended infusion of beta-lactams as a standard of care
  4. Identify methods for effective implementation of rapid diagnostic testing through integration of microbiology expertise in antimicrobial stewardship teams
  5. Explain opportunities for antimicrobial stewardship programs to improve the value of laboratory testing and reduce errors through optimal selection and reporting of tests
  6. Describe approaches for improving the safety of antimicrobial therapy in patients at risk for acute kidney injury, and evaluate optimal antimicrobial drug dosing in patients with kidney dysfunction
  7. Identify core principles of effective leadership techniques and explain how to leverage them within an antimicrobial stewardship program to expand and strengthen the multidisciplinary team
  8. Identify unique challenges of optimizing antimicrobial use in special populations (neonatal, HIV, immunocompromised), and summarize the existing evidence for antimicrobial stewardship interventions in these settings
  9. Describe the clinical implications of difficile infection on patient mortality and quality of life, and outline current evidence and guidelines for the management of severe infection and prevention of recurrence
  10. List three examples of antimicrobial stewardship interventions in outpatient/transition-of-care settings and list barriers and solutions to antimicrobial stewardship in small hospital or outpatient settings